J G Shelton

3.0k total citations · 3 hit papers
11 papers, 2.4k citations indexed

About

J G Shelton is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, J G Shelton has authored 11 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Oncology and 3 papers in Organic Chemistry. Recurrent topics in J G Shelton's work include PI3K/AKT/mTOR signaling in cancer (5 papers), Cytokine Signaling Pathways and Interactions (5 papers) and Quinazolinone synthesis and applications (2 papers). J G Shelton is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (5 papers), Cytokine Signaling Pathways and Interactions (5 papers) and Quinazolinone synthesis and applications (2 papers). J G Shelton collaborates with scholars based in United States and Italy. J G Shelton's co-authors include James A. McCubrey, Linda S. Steelman, Richard A. Franklin, William L. Blalock, Patrick M. Navolanic, Fuju Chang, F. E. Bertrand, Steven C. Pohnert, M. K. White and Martin McMahon and has published in prestigious journals such as Leukemia and PubMed.

In The Last Decade

J G Shelton

11 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy

2003 999 citations Fuju Chang, Patrick M. Navolanic et al. Leukemia profile →
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention

2003 577 citations Fuju Chang, Linda S. Steelman et al. Leukemia profile →
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

2004 555 citations Linda S. Steelman, Steven C. Pohnert et al. Leukemia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J G Shelton United States	11	1.6k	593	395	368	278	11	2.4k
Babita Madan Singapore	27	1.7k 1.1×	730 1.2×	179 0.5×	219 0.6×	204 0.7×	50	2.5k
Alessandra Cappellini Italy	30	1.6k 1.0×	401 0.7×	521 1.3×	218 0.6×	283 1.0×	64	2.2k
Manfred Jücker Germany	30	2.0k 1.3×	904 1.5×	240 0.6×	553 1.5×	518 1.9×	104	3.2k
Baskaran Rajasekaran United States	20	1.6k 1.0×	552 0.9×	238 0.6×	305 0.8×	160 0.6×	25	2.1k
Brigitte Sola France	28	1.3k 0.8×	485 0.8×	293 0.7×	209 0.6×	368 1.3×	101	2.2k
Patrick M. Navolanic United States	19	2.3k 1.4×	1.0k 1.7×	165 0.4×	562 1.5×	324 1.2×	23	3.5k
Eliana Abdelhay Brazil	26	1.1k 0.7×	474 0.8×	204 0.5×	452 1.2×	244 0.9×	125	2.0k
Takayuki Hoshii Japan	23	2.4k 1.5×	558 0.9×	644 1.6×	405 1.1×	572 2.1×	48	3.6k
Anne‐Marie Faussat France	26	1.1k 0.7×	648 1.1×	205 0.5×	242 0.7×	164 0.6×	46	1.9k

Countries citing papers authored by J G Shelton

Since Specialization

Citations

This map shows the geographic impact of J G Shelton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J G Shelton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J G Shelton more than expected).

Fields of papers citing papers by J G Shelton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J G Shelton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J G Shelton. The network helps show where J G Shelton may publish in the future.

Co-authorship network of co-authors of J G Shelton

This figure shows the co-authorship network connecting the top 25 collaborators of J G Shelton. A scholar is included among the top collaborators of J G Shelton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J G Shelton. J G Shelton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Bertrand, F. E., Linda S. Steelman, William H. Chappell, et al.. (2006). Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia. 20(7). 1254–1260. 68 indexed citations

Steelman, Linda S., Steven C. Pohnert, J G Shelton, et al.. (2004). JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 18(2). 189–218. 555 indexed citations breakdown →

Shelton, J G, et al.. (2004). Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors. Leukemia. 19(1). 18–26. 30 indexed citations

Bertrand, F. E., et al.. (2004). Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support. Leukemia. 19(1). 98–102. 31 indexed citations

Blalock, William L., Patrick M. Navolanic, Linda S. Steelman, et al.. (2003). Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. Leukemia. 17(6). 1058–1067. 50 indexed citations

Chang, Fuju, Linda S. Steelman, J G Shelton, et al.. (2003). Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 17(7). 1263–1293. 577 indexed citations breakdown →

Shelton, J G, Linda S. Steelman, William L. Blalock, et al.. (2003). Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia. 17(9). 1765–1782. 40 indexed citations

Chang, Fuju, Patrick M. Navolanic, Linda S. Steelman, et al.. (2003). Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 17(3). 590–603. 999 indexed citations breakdown →

McCubrey, James A., et al.. (2001). Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice. Leukemia. 15(5). 814–818. 20 indexed citations

10.

McCubrey, James A., Linda S. Steelman, William L. Blalock, et al.. (2001). Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells.. PubMed. 25(4). 375–93. 55 indexed citations

11.

Weinstein‐Oppenheimer, Caroline, LS Steelman, P A Algate, et al.. (2000). Effects of deregulated Raf activation on integrin, cytokine-receptor expression and the induction of apoptosis in hematopoietic cells. Leukemia. 14(11). 1921–1938. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact